Prospective cost-effectiveness analysis of genomic profiling in breast cancer

European Journal of Cancer

Volumn 49, Issue 18, 2013, Pages 3773-3779

  Retel V P ^a   Joore, M A ^b,c   Drukker, C A ^a   Bueno De Mesquita, J M ^a   Knauer, M ^d   Van Tinteren, H ^a   Linn, S C ^a   Van Harten, W H ^a,e  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SISTERS OF CHARITY HOSPITAL   (Austria)

^e UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Adjuvant systemic treatment; Breast cancer; Gene expression profiling; Real world cost effectiveness

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SIZE; CLINICAL PRACTICE; COMPUTER PROGRAM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

ADJUVANT SYSTEMIC TREATMENT; BREAST CANCER; GENE EXPRESSION PROFILING; REAL WORLD COST-EFFECTIVENESS;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MARKOV CHAINS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR BURDEN;

EID: 84887989400     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.08.001     Document Type: Article

References (23)

1. R. Sullivan, J. Peppercorn, and K. Sikora Delivering affordable cancer care in high-income countries Lancet Oncol 12 10 2011 933 980
2. LJ Van't Veer, H Dai, and MJ van de Vijver Gene expression profiling predicts clinical outcome of breast cancer Nature 415 6871 2002 530 536
3. M.J. van de Vijver, Y.D. He, and L.J. Van't Veer A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 2002 1999 2009
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
5. S. Mook, L.J. Van't Veer, E.J. Rutgers, M.J. Piccart-Gebhart, and F. Cardoso Individualization of therapy using Mammaprint: from development to the MINDACT Trial Cancer Genomics Proteomics 4 3 2007 147 155
6. J.M. Bueno-de-Mesquita, W.H. van Harten, and V.P. Retèl Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) Lancet Oncol 8 12 2007 1079 1087
7. C.A. Drukker, J.M. Bueno-de-Mesquita, and V.P. Retèl A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study Int J Cancer January 31, 2013 [Epub ahead of print]
8. V.P. Retèl, M.A. Joore, M. Knauer, S.C. Linn, M. Hauptmann, and W.H. Harten Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer Eur J Cancer 46 8 2010 1382 1391
9. V.P. Retèl, J.M. Bueno-de-Mesquita, and M.J. Hummel Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics Int J Technol Assess Health Care 25 1 2009 73 83
10. M. Buyse, S. Loi, and L.J. Van't Veer Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 98 17 2006 1183 1192
11. J.M. Bueno-de-Mesquita, S.C. Linn, and R. Keijzer Validation of 70-gene prognosis signature in node-negative breast cancer Breast Cancer Res Treat 117 3 2009 483 495
12. V.P. Retèl, M.A. Joore, S.C. Linn, E.J. Rutgers, and W.H. van Harten Scenario drafting to anticipate future developments in technology assessment BMC Res Notes 5 2012 442
13. Kwaliteitsinstituut voor de Gezondheidszorg CBO VvlK. Adjuvante Systemische Therapie voor het Operabel Mammacarcinoom. Richtlijn Behandeling van het Mammacarcinoom; 2004. p. 46-70.
14. I.A. Olivotto, C.D. Bajdik, and P.M. Ravdin Population-based validation of the prognostic model ADJUVANT! For early breast cancer J Clin Oncol 23 2005 2716 2725
15. P.M. Ravdin, L.A. Siminoff, and G.J. Davis Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 19 2001 980 991
16. M. Lidgren, B. Jonsson, C. Rehnberg, N. Willking, and J. Bergh Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer Ann Oncol 19 3 2008 487 495
17. M. Lidgren, N. Wilking, B. Jonsson, and C. Rehnberg Health related quality of life in different states of breast cancer Qual Life Res 16 6 2007 1073 1081
18. M.F. Drummond, and T.O. Jefferson Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party BMJ 313 7052 1996 275 283
19. M.C. Weinstein Recent developments in decision-analytic modelling for economic evaluation Pharmacoeconomics 24 11 2006 1043 1053
20. E. Fenwick, K. Claxton, and M. Sculpher Representing uncertainty: the role of cost-effectiveness acceptability curves Health Econ 10 8 2001 779 787
21. J. Appleby, N. Devlin, and D. Parkin NICE's cost effectiveness threshold BMJ 335 7616 2007 358 359
22. M. Lothgren, and N. Zethraeus Definition, interpretation and calculation of cost-effectiveness acceptability curves Health Econ 9 7 2000 623 630
23. F. Cardoso, L.J. Van't Veer, E. Rutgers, S. Loi, S. Mook, and M.J. Piccart-Gebhart Clinical application of the 70-gene profile: the MINDACT trial J Clin Oncol 26 5 2008 729 735